130 related articles for article (PubMed ID: 9516848)
1. The prognostic value of MDR1 gene expression in primary untreated neuroblastoma.
Haber M; Bordow SB; Haber PS; Marshall GM; Stewart BW; Norris MD
Eur J Cancer; 1997 Oct; 33(12):2031-6. PubMed ID: 9516848
[TBL] [Abstract][Full Text] [Related]
2. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma.
Norris MD; Bordow SB; Marshall GM; Haber PS; Cohn SL; Haber M
N Engl J Med; 1996 Jan; 334(4):231-8. PubMed ID: 8532000
[TBL] [Abstract][Full Text] [Related]
3. Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma.
Norris MD; Bordow SB; Haber PS; Marshall GM; Kavallaris M; Madafiglio J; Cohn SL; Salwen H; Schmidt ML; Hipfner DR; Cole SP; Deeley RG; Haber M
Eur J Cancer; 1997 Oct; 33(12):1911-6. PubMed ID: 9516823
[TBL] [Abstract][Full Text] [Related]
4. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.
Haber M; Smith J; Bordow SB; Flemming C; Cohn SL; London WB; Marshall GM; Norris MD
J Clin Oncol; 2006 Apr; 24(10):1546-53. PubMed ID: 16575006
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma.
Bordow SB; Norris MD; Haber PS; Marshall GM; Haber M
J Clin Oncol; 1998 Oct; 16(10):3286-94. PubMed ID: 9779703
[TBL] [Abstract][Full Text] [Related]
6. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
[TBL] [Abstract][Full Text] [Related]
7. Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours.
Oda Y; Röse I; Radig K; Wagemann W; Mittler U; Roessner A
Virchows Arch; 1997 Feb; 430(2):99-105. PubMed ID: 9083512
[TBL] [Abstract][Full Text] [Related]
8. Expression analysis of multidrug resistance associated genes in neuroblastomas.
Bader P; Schilling F; Schlaud M; Girgert R; Handgretinger R; Klingebiel T; Treuner J; Liu C; Niethammer D; Beck JF
Oncol Rep; 1999; 6(5):1143-6. PubMed ID: 10425316
[TBL] [Abstract][Full Text] [Related]
9. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
10. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
[TBL] [Abstract][Full Text] [Related]
11. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
12. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma.
Kramer K; Cheung NK; Gerald WL; LaQuaglia M; Kushner BH; LeClerc JM; LeSauter L; Saragovi HU
Eur J Cancer; 1997 Oct; 33(12):2098-100. PubMed ID: 9516861
[TBL] [Abstract][Full Text] [Related]
13. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells.
Haber M; Bordow SB; Gilbert J; Madafiglio J; Kavallaris M; Marshall GM; Mechetner EB; Fruehauf JP; Tee L; Cohn SL; Salwen H; Schmidt ML; Norris MD
Oncogene; 1999 Apr; 18(17):2777-82. PubMed ID: 10348353
[TBL] [Abstract][Full Text] [Related]
15. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
16. Expression of MRP and cMOAT in childhood neuroblastomas and malignant liver tumors and its relevance to clinical behavior.
Matsunaga T; Shirasawa H; Hishiki T; Enomoto H; Kouchi K; Ohtsuka Y; Iwai J; Yoshida H; Tanabe M; Kobayashi S; Asano T; Etoh T; Nishi Y; Ohnuma N
Jpn J Cancer Res; 1998 Dec; 89(12):1276-83. PubMed ID: 10081488
[TBL] [Abstract][Full Text] [Related]
17. Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma.
Dhooge CR; De Moerloose BM; Benoit YC; Van Roy N; Philippé ; Laureys GG
Cancer; 1997 Oct; 80(7):1250-7. PubMed ID: 9317175
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC
J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of MDR1 gene expression in neuroblastoma: results of a multivariate analysis.
Bénard J; Bourhis J; de Vathaire F; Ferrandis E; Terrier-Lacombe MJ; Lemerle J; Riou G; Hartmann O
Prog Clin Biol Res; 1994; 385():111-6. PubMed ID: 7972202
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma.
Combaret V; Gross N; Lasset C; Frappaz D; Beretta-Brognara C; Philip T; Beck D; Favrot MC
Eur J Cancer; 1997 Oct; 33(12):2101-5. PubMed ID: 9516862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
